Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors

Published:2021-04 Issue:15 Volume:127 Page:2648-2656
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Sasaki Koji¹^ORCID,Kantarjian Hagop M.¹^ORCID,Short Nicholas J.¹^ORCID,Samra Bachar¹,Khoury Joseph D.²,Kanagal Shamanna Rashmi²^ORCID,Konopleva Marina¹,Jain Nitin¹,DiNardo Courtney D.¹^ORCID,Khouri Rita¹,Garcia‐Manero Guillermo¹^ORCID,Kadia Tapan M.¹^ORCID,Wierda William G.¹,Khouri Issa F.³^ORCID,Kebriaei Partow³,Mehta Rohtesh S.³^ORCID,Champlin Richard E.³,Garris Rebecca¹,Cheung Cora Marie¹,Daver Naval¹^ORCID,Thompson Philip A.¹,Yilmaz Musa¹,Ravandi Farhad¹,Jabbour Elias¹^ORCID

Affiliation:

1. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas

2. Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas

3. Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33529

Reference24 articles.

1. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia

2. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

3. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

4. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

5. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia can be Treated with Chemotherapy-Free Regimens without Transplant;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Transplant in Adult ALL: Who and When;Clinical Lymphoma Myeloma and Leukemia;2024-09

4. SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-07

5. Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions;Leukemia;2024-06-20